QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
Top-Rated Stocks  
NASDAQ:PNT

POINT Biopharma Global - PNT Stock Forecast, Price & News

$8.10
+0.15 (+1.89%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.81
▼
$8.33
50-Day Range
$6.49
▼
$8.00
52-Week Range
$5.22
▼
$10.98
Volume
1.49 million shs
Average Volume
593,213 shs
Market Capitalization
$842.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.13

POINT Biopharma Global MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
99.1% Upside
$16.13 Price Target
Short Interest
Bearish
10.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of POINT Biopharma Global in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$229,158 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.49) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

522nd out of 1,030 stocks

Pharmaceutical Preparations Industry

262nd out of 502 stocks

See Top Rated MarketRank™ Stocks Here

PNT stock logo

About POINT Biopharma Global (NASDAQ:PNT) Stock

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Stock News Headlines

February 2, 2023 | americanbankingnews.com
Brokerages Set POINT Biopharma Global Inc. (NASDAQ:PNT) PT at $16.13
January 18, 2023 | seekingalpha.com
PNT POINT Biopharma Global Inc.
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 12, 2023 | finance.yahoo.com
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
December 20, 2022 | finance.yahoo.com
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
December 16, 2022 | finance.yahoo.com
When Will POINT Biopharma Global Inc. (NASDAQ:PNT) Turn A Profit?
November 29, 2022 | finance.yahoo.com
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
November 29, 2022 | seekingalpha.com
Lantheus: Sell Thesis Missing These Key Factors
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
November 28, 2022 | seekingalpha.com
Lantheus Holdings: May Be Time To Buy After Big Correction
November 22, 2022 | benzinga.com
311K Reasons To Be Bullish On POINT Biopharma Global Stock
November 15, 2022 | markets.businessinsider.com
Analyst Ratings for POINT Biopharma Global
November 14, 2022 | finance.yahoo.com
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
November 14, 2022 | seekingalpha.com
Point Biopharma slumps 35% on license deal with Lantheus for cancer drugs
November 14, 2022 | finance.yahoo.com
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
November 11, 2022 | msn.com
How Much Upside is Left in POINT Biopharma Global Inc. (PNT)? Wall Street Analysts Think 212%
November 11, 2022 | morningstar.com
North American Morning Briefing: Fed Hopes, China -2-
November 10, 2022 | msn.com
Why Earnings Season Could Be Great for POINT Biopharma (PNT)
October 26, 2022 | finance.yahoo.com
Wall Street Analysts Think POINT Biopharma Global Inc. (PNT) Could Surge 235%: Read This Before Placing a Bet
October 17, 2022 | finance.yahoo.com
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 | finance.yahoo.com
Calculating The Intrinsic Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
October 10, 2022 | investing.com
UPDATE: Oppenheimer Starts POINT Biopharma Global Inc. at Outperform
September 16, 2022 | finance.yahoo.com
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 14, 2022 | marketwatch.com
POINT Biopharma Shares Slide After Public Offering >PNT
September 14, 2022 | nasdaq.com
POINT Biopharma Global Prices Public Offering Of 13.90 Mln Shares At $9.00/shr
September 13, 2022 | finance.yahoo.com
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 | finance.yahoo.com
POINT Biopharma Announces Proposed Public Offering of Common Stock
See More Headlines
Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PNT
CUSIP
N/A
CIK
1811764
Web
www.pointbiopharma.com
Phone
317-543-9957
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.13
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+99.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-45,900,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.08%
Return on Assets
-29.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.84
Quick Ratio
17.84

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.83 per share
Price / Book
2.86

Miscellaneous

Outstanding Shares
104,030,000
Free Float
84,572,000
Market Cap
$842.64 million
Optionable
Not Optionable
Beta
0.12

Key Executives

  • Mr. Allan Charles Silber (Age 72)
    Exec. Chairman
    Comp: $677.8k
  • Dr. Joe A. McCann Ph.D. (Age 44)
    CEO & Director
    Comp: $740.31k
  • Dr. Neil E. Fleshner FRCSC (Age 59)
    M.D., M.PH, Chief Medical Officer & Director
    Comp: $227.5k
  • Ms. Jessica D. Jensen M.P.H. (Age 41)
    MPH, Exec. VP of Clinical Devel.
    Comp: $541.59k
  • Mr. Bill Demers B.B.A. (Age 64)
    F.C.A., FCPA, Chief Financial Officer
  • Ms. Justyna Kelly M.Sc. (Age 37)
    Chief Operating Officer
  • Ms. Donna Husack B.A.
    VP of HR
  • Mr. Ari Shomair
    VP of Corp. Affairs & Chief of Staff
  • Dr. Myra Rosario Herle Ph.D.
    R.Ph., Exec. VP of Regulatory Affairs
  • Dr. Matthew P. Vincent J.D.
    Ph.D., Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PNT Stock - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PNT shares.
View PNT analyst ratings or view top-rated stocks.

What is POINT Biopharma Global's stock price forecast for 2023?

9 Wall Street research analysts have issued 12-month price targets for POINT Biopharma Global's shares. Their PNT share price forecasts range from $10.00 to $22.00. On average, they predict the company's share price to reach $16.13 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts price targets for PNT or view top-rated stocks among Wall Street analysts.

How have PNT shares performed in 2023?

POINT Biopharma Global's stock was trading at $7.29 at the start of the year. Since then, PNT shares have increased by 11.9% and is now trading at $8.16.
View the best growth stocks for 2023 here.

When is POINT Biopharma Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our PNT earnings forecast.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) announced its earnings results on Monday, November, 14th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02.

What is POINT Biopharma Global's stock symbol?

POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."

Who are POINT Biopharma Global's major shareholders?

POINT Biopharma Global's stock is owned by many different retail and institutional investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.01%), ProShare Advisors LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allan C Silber, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin.
View institutional ownership trends.

How do I buy shares of POINT Biopharma Global?

Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is POINT Biopharma Global's stock price today?

One share of PNT stock can currently be purchased for approximately $8.16.

How much money does POINT Biopharma Global make?

POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $848.88 million. The company earns $-45,900,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How can I contact POINT Biopharma Global?

POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 317-543-9957.

This page (NASDAQ:PNT) was last updated on 2/2/2023 by MarketBeat.com Staff